Citigroup’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-47,005
| Closed | -$1.11M | – | 5908 |
|
|
2023
Q4 | $1.11M | Buy |
47,005
+28,591
| +155% | +$509K | ﹤0.01% | 2740 |
|
|
2023
Q3 | $275K | Sell |
18,414
-30,183
| -62% | -$400K | ﹤0.01% | 3468 |
|
|
2023
Q2 | $532K | Sell |
48,597
-185,699
| -79% | -$1.73M | ﹤0.01% | 3329 |
|
|
2023
Q1 | $2.04M | Buy |
234,296
+4,709
| +2% | +$37.7K | ﹤0.01% | 2008 |
|
|
2022
Q4 | $1.44M | Buy |
229,587
+118,504
| +107% | +$450K | ﹤0.01% | 2295 |
|
|
2022
Q3 | $389K | Sell |
111,083
-151,321
| -58% | -$544K | ﹤0.01% | 3418 |
|
|
2022
Q2 | $774K | Buy |
262,404
+256,894
| +4,662% | +$614K | ﹤0.01% | 2880 |
|
|
2022
Q1 | $17K | Sell |
5,510
-15,220
| -73% | -$47.9K | ﹤0.01% | 5260 |
|
|
2021
Q4 | $70K | Buy |
20,730
+8,706
| +72% | +$33.1K | ﹤0.01% | 4921 |
|
|
2021
Q3 | $44K | Buy |
12,024
+4,225
| +54% | +$16.6K | ﹤0.01% | 4808 |
|
|
2021
Q2 | $34K | Buy |
7,799
+234
| +3% | +$1.04K | ﹤0.01% | 5014 |
|
|
2021
Q1 | $34K | Sell |
7,565
-42,983
| -85% | -$231K | ﹤0.01% | 4936 |
|
|
2020
Q4 | $291K | Buy |
50,548
+34,224
| +210% | +$259K | ﹤0.01% | 4694 |
|
|
2020
Q3 | $119K | Sell |
16,324
-876,140
| -98% | -$4.68M | ﹤0.01% | 4981 |
|
|
2020
Q2 | $3.12M | Sell |
892,464
-10,891
| -1% | -$31.4K | ﹤0.01% | 2319 |
|
|
2020
Q1 | $1.34M | Sell |
903,355
-443,935
| -33% | -$745K | ﹤0.01% | 2878 |
|
|
2019
Q4 | $2.64M | Buy |
1,347,290
+355,463
| +36% | +$1.34M | ﹤0.01% | 2696 |
|
|
2019
Q3 | $5.08M | Buy |
991,827
+409,692
| +70% | +$2.48M | ﹤0.01% | 1926 |
|
|
2019
Q2 | $4.17M | Buy |
582,135
+562,167
| +2,815% | +$6.37M | ﹤0.01% | 2123 |
|
|
2019
Q1 | $265K | Buy |
19,968
+2
| +0% | +$21 | ﹤0.01% | 4828 |
|
|
2018
Q4 | $157K | Buy |
19,966
+3,000
| +18% | +$28.6K | ﹤0.01% | 5256 |
|
|
2018
Q3 | $188K | Buy |
16,966
+6,751
| +66% | +$83.9K | ﹤0.01% | 5323 |
|
|
2018
Q2 | $137K | Buy |
10,215
+9,297
| +1,013% | +$116K | ﹤0.01% | 5424 |
|
|
2018
Q1 | $12K | Buy |
+918
| New | +$11.4K | ﹤0.01% | 6988 |
|
|
2016
Q2 | – | Sell |
-324
| Closed | – | – | 7522 |
|
|
2016
Q1 | $0 | Buy |
+324
| New | +$401 | ﹤0.01% | 7844 |
|
|
2015
Q1 | – | Sell |
-482
| Closed | -$5K | – | 7495 |
|
|
2014
Q4 | $5K | Buy |
482
+439
| +1,021% | +$3.53K | ﹤0.01% | 6685 |
|
|
2014
Q3 | $0 | Buy |
+43
| New | +$264 | ﹤0.01% | 7358 |
|
Other funds holding CBAY
Citigroup's CBAY Position: Q1 2024 in Review
Citigroup sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 47,005 shares — an estimated $1.11M sold.
Citigroup first reported a position in CBAY in Q3 2014 and held it in 27 quarters. The position peaked at $5.08M in Q3 2019. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Citigroup reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Citigroup sold 47,005 Cymabay Therapeutics shares in Q1 2024, an estimated $1.11M.
- Citigroup first reported a position in Cymabay Therapeutics in Q3 2014 and held it in 27 quarters.
- Citigroup's Cymabay Therapeutics position peaked at $5.08M in Q3 2019.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.